Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lorlatinib

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Soaring sales of Pfizer’s Prevnar lead to calls for price cut

Revenue from the family of pneumonia vaccines rose 43% in the fourth quarter

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa gets FDA OK

Wins accelerated US approval for non-small cell lung cancer

- PMLiVE

Quintiles wins New Models of Care award at PMEA

Rewarded for its rheumatology project for Pfizer

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

- PMLiVE

Xalkori set for rapid review in new lung cancer indication

Pfizer could produce first FDA-approved biomarker-driven therapy for ROS1-positive NSCLC

- PMLiVE

Pfizer signs $1bn cancer antibody deal with BioAtla

Aims to overcome one of the limitations of antibody-drug conjugate drugs

- PMLiVE

UK patients get early access to AZ’s lung cancer drug Tagrisso

The treatment is the fourth made available under the EAMS

- PMLiVE

UK site a casualty as Pfizer reduces pain R&D

Will shut down Granta Park facility in Cambridge with loss of 120 jobs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links